Cosmo Pharmaceuticals N.V. reports news across its life sciences business, including MedTech AI, dermatology, gastrointestinal disease programs, and contract development and manufacturing. Company updates frequently cover the GI Genius™ platform and real-time medical AI for endoscopy, dermatology assets such as Clascoterone 5% topical solution and Winlevi®, and gastroenterology research programs in bile acid diarrhea and distal ulcerative colitis.
Recurring disclosures also include annual results, recurring revenue trends, dividend actions, AGM voting outcomes, ESG reporting, board and remuneration matters, and capital-structure authorizations. Partnership and R&D collaboration announcements describe how Cosmo extends AI-enabled medical technology into additional clinical applications while maintaining a broader portfolio of pharmaceutical and CDMO activities.
Cosmo Pharmaceuticals NV (SIX: COPN) will hold a telephone conference on March 26, 2021, at 2:00 PM CET to discuss its 2020 financial results and 2021 outlook. CEO Alessandro Della Chà and CFO Niall Donnelly will present during this session. Dial-in numbers are provided for participants from Switzerland, the UK, and the US. The presentation materials will be available on the company's website from 7:00 AM CET on the same day. Cosmo focuses on developing products for gastrointestinal disorders and has partnered with Medtronic for its AI device.